Resistance to β-lactam antibiotics

Cellular and Molecular Life Sciences

Volumn 61, Issue 17, 2004, Pages 2200-2223

  Poole, K ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

lactam; lactamase; Efflux; Impermeability; Penicillin binding protein

Indexed keywords

ANTIBIOTIC AGENT; AZTREONAM; BACTERIAL ENZYME; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; BIAPENEM; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOTAXIME; CEFPIROME; CEFPODOXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CEPHALOSPORINASE; CEPHAMYCIN DERIVATIVE; CLAVULANIC ACID; CLOXACILLIN; ERTAPENEM; FROPENEM; IMIPENEM; MEROPENEM; MONOBACTAM DERIVATIVE; OXACILLIN; PANIPENEM; PENICILLIN BINDING PROTEIN; PENICILLIN DERIVATIVE; PENICILLINASE; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM MUTANT; BINDING AFFINITY; DRUG PROTEIN BINDING; DRUG TRANSPORT; ENTEROCOCCUS; ENZYME ACTIVE SITE; ENZYME STABILITY; ENZYME SUBSTRATE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CARRIER PROTEINS; DRUG RESISTANCE, MULTIPLE; HEXOSYLTRANSFERASES; MURAMOYLPENTAPEPTIDE CARBOXYPEPTIDASE; PENICILLIN-BINDING PROTEINS; PEPTIDYL TRANSFERASES; PERMEABILITY; PLASMIDS;

BACTERIA (MICROORGANISMS); ENTEROCOCCUS; NEGIBACTERIA; POSIBACTERIA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 4644301876     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00018-004-4060-9     Document Type: Review

References (404)

1. Bartlett J. G. 2003. 2003-2004 Pocket Book of Infectious Disease Therapy. Lippincott Williams and Wilkins, Baltimore
2. Essack S. Y. (2001) The development of β-lactam antibiotics in response to the evolution of β-lactamases. Pharm. Res. 18: 1391-1399
3. Siu L. K. (2002) Antibiotics: action and resistance in gram-negative bacteria. J. Microbiol. Immunol. Infect. 35: 1-11
4. Dalhoff A. and Thomson C. J. (2003) The art of fusion: from penams and cephems to penems. Chemotherapy (Basel) 49: 105-120
5. Bayles K. W. (2000) The bactericidal action of penicillin: new clues to an unsolved mystery. Trends Microbiol. 8: 274-278
6. Bell J. M. and Turnidge J. D. (2002) High prevalence of oxacillin-resistant Staphylococcus aureus isolates from hospitalized patients in Asia-Pacific and South Africa: results from SENTRY antimicrobial surveillance program, 1998-1999. Antimicrob. Agents Chemother. 46: 879-881
7. Fluit A. C., Wielders C. L., Verhoef J. and Schmitz F. J. (2001) Epidemiology and susceptibility of 3,051 Staphylococcus aureus isolates from 25 university hospitals participating in the European SENTRY study. J. Clin. Microbiol. 39: 3727-3732
8. Friedland I., Stinson L., Ikaiddi M., Harm S. and Woods G. L. (2003) Resistance in Enterobacteriaceae: results of a multicenter surveillance study, 1995-2000. Infect. Control Hosp. Epidemiol. 24: 607-612
9. Tzouvelekis L. S., Lukova V., Tassios P. T., Fluit A. C., Jones R. N. and Legakis N. J. (2003) Resistance to β-lactams among blood isolates of Salmonella spp. in European hospitals: results from the SENTRY Antimicrobial Surveillance Program 1997-1998. Clin. Microbiol. Infect. 9: 149-152
10. Clark N. M., Patterson J. and Lynch J. P. III (2003) Antimicrobial resistance among gram-negative organisms in the intensive care unit. Curr. Opin. Crit. Care 9: 413-423
11. Goossens H. (2003) Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group. Clin. Microbiol. Infect. 9: 980-983
12. Majiduddin F. K., Materon I. C. and Palzkill T. G. (2002) Molecular analysis of P-lactamase structure and function. Int. J. Med. Microbiol. 292: 127-137
13. Helfand M. S. and Bonomo R. A. (2003) β-lactamases: a survey of protein diversity. Curr. Drug Targets. Infect. Disord. 3: 9-23
14. Massova I. and Mobashery S. (1998) Kinship and diversification of bacterial penicillin-binding proteins and β-lactamases. Antimicrob. Agents Chemother. 42: 1-17
15. Livermore D. M. (1995) β-lactamases in laboratory and clinical resistance. Clin. Microbiol. Rev. 8: 557-584
16. Rowe-Magnus D. A. and Mazel D. (2002) The role of integrons in antibiotic resistance gene capture. Int. J. Med. Microbiol. 292: 115-125
17. Knox J. R. (1995) Extended-spectrum and inhibitor-resistant TEM-type β-lactamases: mutations, specificity and three-dimensional structure. Antimicrob. Agents Chemother. 39: 2593-2601
18. Philippon A., Arlet G. and Jacoby G. A. (2002) Plasmid-determined AmpC-type β-lactamases. Antimicrob. Agents Chemother. 46: 1-11
19. Walther-Rasmussen J. and Hoiby N. (2002) Plasmid-borne AmpC β-lactamases. Can. J. Microbiol. 48: 479-493
20. Bradford P. A. (2001) Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology and detection of this important resistance threat. Clin. Microbiol Rev. 14: 933-951
21. Sturenburg E. and Mack D. (2003) Extended-spectrum β-lactamases: implications for the clinical microbiology laboratory, therapy and infection control. J. Infect. 47: 273-295
22. Rupp M. E. and Fey P. D. (2003) Extended spectrum β-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. Drugs 63: 353-365
23. Poirel L. and Nordmann P. (2002) Acquired carbapenem-hydrolyzing β-lactamases and their genetic support. Curr. Pharm. Biotechnol. 3: 117-127
24. Nordmann P. and Poirel L. (2002) Emerging carbapenemases in Gram-negative aerobes. Clin. Microbiol. Infect. 8: 321-331
25. Garcia-Rodriguez J. A. and Jones R. N. (2002) Antimicrobial resistance in gram-negative isolates from European intensive care units: data from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme. J. Chemother. 14: 25-32
26. Bell J. M., Turnidge J. D. and Jones R. N. (2003) Prevalence of extended-spectrum β-lactamase-producing Enterobacter cloacae in the Asia-Pacific region: results from the SENTRY antimicrobial surveillance program, 1998 to 2001. Antimicrob. Agents Chemother. 47: 3989-3993
27. Lee S. H. and Jeong S. H. (2002) Antibiotic susceptibility of bacterial strains isolated from patients with various infections. Lett. Appl. Microbiol. 34: 215-221
28. Jain A., Roy I., Gupta M. K., Kumar M. and Agarwal S. K. (2003) Prevalence of extended-spectrum β-lactamase-producing Gram-negative bacteria in septicaemic neonates in a tertiary care hospital. J. Med. Microbiol. 52: 421-425
29. Goossens H. (2001) MYSTIC program: summary of European data from 1997 to 2000. Diagn. Microbiol. Infect. Dis. 41: 183-189
30. Bonfiglio G., Perilli M., Stefani S., Amicosante G. and Nicoletti G. (2002) Prevalence of extended spectrum β-lactamases among Enterobacteriaceae: an Italian survey. Int. J. Antimicrob. Agents 19: 213-217
31. Sanguinetti M., Posteraro B., Spanu T., Ciccaglione D., Romano L., Fiori B. et al. (2003) Characterization of clinical isolates of Enterobacteriaceae from Italy by the BD Phoenix extended-spectrum β-lactamase detection method. J. Clin. Microbiol. 41: 1463-1468
32. Quinteros M., Radice M., Gardella N., Rodriguez M. M., Costa N., Korbenfeld D. et al. (2003) Extended-spectrum β-lactamases in enterobacteriaceae in Buenos Aires, Argentina, public hospitals. Antimicrob. Agents Chemother. 47: 2864-2867
33. Winokur P. L., Canton R., Casellas J. M. and Legakis N. (2001) Variations in the prevalence of strains expressing an extended-spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas and the Western Pacific region. Clin. Infect. Dis. 32 Suppl 2: S94-103
34. Albertini M. T., Benoit C., Berardi L., Berrouane Y., Boisivon A., Cahen P. et al. (2002) Surveillance of methicillin-resistant Staphylococcus aureus (MRSA) and Enterobacteriaceae producing extended-spectrum β-lactamase (ESBLE) in Northern France: a five-year multicentre incidence study. J. Hosp. Infect. 52: 107-113
35. Jones R. N. and Pfaller M. A. (2003) Antimicrobial activity against strains of Escherichia coli and Klebsiella spp. with resistance phenotypes consistent with an extended-spectrum β-lactamase in Europe. Clin. Microbiol. Infect. 9: 708-712
36. Moland E. S., Black J. A., Ourada J., Reisbig M. D., Hanson N. D. and Thomson K. S. (2002) Occurrence of newer β-lactamases in Klebsiella pneumoniae isolates from 24 U.S. hospitals. Antimicrob. Agents Chemother. 46: 3837-3842
37. Mulvey M. R., Bryce E., Boyd D., Marianna O.-A., Christianson S., Simor A. E. et al. (2004) Ambler class A extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella spp. in Canadian hospitals. Antimicrob. Agents Chemother. 48: 1204-1214
38. Essack S. Y. (2000) Treatment options for extended-spectrum β-lactamase-producers. FEMS Microbiol. Lett. 190: 181-184
39. Bujdakova H., Lausova A., Jankovicova S., Prodinger W. M., Kallova J., Milosovic P. et al. (1998) Study of β-lactam resistance in ceftazidime-resistant clinical isolates of Enterobacteriaceae. Int. J. Antimicrob. Agents 10: 135-141
40. Zanetti G., Bally F., Greub G., Garbino J., Kinge T., Lew D. et al. (2003) Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob. Agents Chemother. 47: 3442-3447
41. Gottlieb T. and Wolfson C. (2000) Comparison of the MICs of cefepime for extended-spectrum β-lactamase-producing and non-extended-spectrum β-lactamase-producing strains of Enterobacter cloacae. J. Antimicrob. Chemother. 46: 330-331
42. Naumiuk L., Samet A. and Dziemaszkiewicz E. (2001) Cefepime in vitro activity against derepressed extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Enterobacter cloacae by a disc diffusion method. J. Antimicrob. Chemother. 48: 321-322
43. Bedenic B., Beader N. and Zagar Z. (2001) Effect of inoculum size on the antibacterial activity of cefpirome and cefepime against Klebsiella pneumoniae strains producing SHV extended-spectrum β-lactamases. Clin. Microbiol. Infect. 7: 626-635
44. Thomson K. S. and Moland E. S. (2001) Cefepime, piperacillin-tazobactam and the inoculum effect in tests with extended-spectrum β-lactamase- producing Enterobacteriaceae. Antimicrob. Agents Chemother. 45. 3548-3554
45. Burgess D. S., Hall R. G., Lewis J. S., Jorgensen J. H. and Patterson J. E. (2003) Clinical and microbiologic analysis of a hospital's extended-spectrum β-lactamase-producing isolates over a 2-year period. Pharmacotherapy 23: 1232-1237
46. Crowley B., Benedi V. J. and Domenech-Sanchez A. (2002) Expression of SHV-2 β-lactamase and of reduced amounts of OmpK36 porin in Klebsiella pneumoniae results in increased resistance to cephalosporins and carbapenems. Antimicrob. Agents Chemother. 46: 3679-3682
47. Melano R., Corso A., Petroni A., Centron D., Orman B., Pereyra A. et al. (2003) Multiple antibiotic-resistance mechanisms including a novel combination of extended-spectrum β-lactamases in a Klebsiella pneumoniae clinical strain isolated in Argentina. J. Antimicrob. Chemother. 52: 36-42
48. Barlow M. and Hall B. G. (2003) Experimental prediction of the natural evolution of antibiotic resistance. Genetics 163: 1237-1241
49. Bonnet R. (2004) Growing group of extended-spectrum β-lactamases: the CTX-M enzymes. Antimicrob. Agents Chemother. 48: 1-14
50. Xiong Z., Zhu D., Wang F., Zhang Y., Okamoto R. and Inoue M. (2002) Investigation of extended-spectrum β-lactamase in Klebsiellae pneumoniae and Escherichia coli from China. Diagn. Microbiol. Infect. Dis. 44: 195-200
51. Preston K. E., Graffunder E. M., Evans A. M. and Venezia R. A. (2003) Survey of plasmid-associated genetic markers in enterobacteriaceae with reduced susceptibilities to cephalosporins. Antimicrob. Agents Chemother. 47: 2179-2185
52. Spanu T., Luzzaro F., Perilli M., Amicosante G., Toniolo A. and Fadda G. (2002) Occurrence of extended-spectrum β-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to β-lactams and other antimicrobial drugs. Antimicrob. Agents Chemother. 46: 196-202
53. Mazzariol A., Zuliani J., Fontana R. and Cornaglia G. (2003) Isolation from blood culture of a Leclercia adecarboxylata strain producing an SHV-12 extended-spectrum β-lactamase. J. Clin. Microbiol. 41: 1738-1739
54. Villa L., Mammina C., Miriagou V., Tzouvelekis L. S., Tassios P. T., Nastasi A. et al. (2002) Multidrug and broad-spectrum cephalosporin resistance among Salmonella enterica serotype Enteritidis clinical isolates in southern Italy. J. Clin. Microbiol. 40: 2662-2665
55. Dhawan B., Bonnet R., Shukla N. K., Mathur P., Das B. K. and Kapil A. (2003) Infection with an extended-spectrum β-lactamase-producing strain of Serratia marcescens following tongue reconstruction. J. Clin. Microbiol. 41: 2233-2234
56. Chanawong A., M'Zali F. H., Heritage J., Lulitanond A. and Hawkey P. M. (2001) SHV-12, SHV-5, SHV-2a and VEB-1 extended-spectrum β-lactamases in Gram-negative bacteria isolated in a university hospital in Thailand. J. Antimicrob. Chemother. 48: 839-852
57. Neonakis I. K., Scoulica E. V., Dimitriou S. K., Gikas A. I. and Tselentis Y. J. (2003) Molecular epidemiology of extended-spectrum β-lactamases produced by clinical isolates in a university hospital in Greece: detection of SHV-5 in Pseudomonas aeruginosa and prevalence of SHV-12. Microb. Drug Resist. 9: 161-165
58. TEM-21 gene located on a chromosomal interrupted TnA type transposon. Antimicrob. Agents Chemother. 46: 3624-3626
59. Marchandin H., Godreuil S., Darbas H., Jean-Pierre H., Jumas-Bilak E., Chanal C. et al. (2003) Extended-spectrum β-lactamase TEM-24 in an Aeromonas clinical strain: acquisition from the prevalent Enterobacter aerogenes clone in France. Antimicrob. Agents Chemother. 47: 3994-3995
60. Nordmann P. and Guibert M. (1998) Extended-spectrum β-lactamases in Pseudomonas aeruginosa. J. Antimicrob. Chemother. 42: 128-131
61. Joshi S. G., Litake G. M., Ghole V. S. and Niphadkar K. B. (2003) Plasmid-borne extended-spectrum β-lactamase in a clinical isolate of Acinetobacter baumannii. J. Med. Microbiol. 52: 1125-1127
62. Naas T., Philippon L., Poirel L., Ronco E. and Nordmann P. (1999) An SHV-derived extended-spectrum β-lactamase in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 43: 1281-1284
63. Bert F., Branger C. and Lambert-Zechovsky N. (2002) Identification of PSE and OXA β-lactamase genes in Pseudomonas aeruginosa using PCR-restriction fragment length polymorphism. J. Antimicrob. Chemother. 50: 11-18
64. Hujer A. M., Hujer K. M. and Bonomo R. A. (2001) Mutagenesis of amino acid residues in the SHV-1 β-lactamase: the premier role of Gly238Ser in penicillin and cephalosporin resistance. Biochim. Biophys. Acta 1547: 37-50
65. Wang X., Minasov G. and Shoichet B. K. (2002) Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs. J. Mol. Biol. 320: 85-95
66. Orencia M. C., Yoon J. S., Ness J. E., Stemmer W. P. and Stevens R. C. (2001) Predicting the emergence of antibiotic resistance by directed evolution and structural analysis. Nat. Struct. Biol. 8. 238-242
67. Nukaga M., Mayama K., Hujer A. M., Bonomo R. A. and Knox J. R. (2003) Ultrahigh resolution structure of a class A β-lactamase: on the mechanism and specificity of the extended-spectrum SHV-2 enzyme. J. Mol. Biol. 328: 289-301
68. Tranier S., Bouthors A. T., Maveyraud L., Guillet V., Sougakoff W. and Samama J. P. (2000) The high resolution crystal structure for class A β-lactamase PER-1 reveals the bases for its increase in breadth of activity. J. Biol. Chem. 275: 28075-28082
69. Zawadzke L. E., Smith T. J. and Herzberg O. (1995) An engineered Staphylococcus aureus PC1 β-lactamase that hydrolyses third-generation cephalosporins. Protein Eng. 8: 1275-1285
70. Ibuka A. S., Ishii Y., Galleni M., Ishiguro M., Yamaguchi K., Frere J. M. et al. (2003) Crystal structure of extended-spectrum β-lactamase Toho-1: insights into the molecular mechanism for catalytic reaction and substrate specificity expansion. Biochemistry 42: 10634-10643
71. Nukaga M., Mayama K., Crichlow G. V. and Knox J. R. (2002) Structure of an extended-spectrum class A β-lactamase from Proteus vulgaris K1. J. Mol. Biol. 317: 109-117
72. Arpin C., Labia R., Dubois V., Noury P., Souquet M. and Quentin C. (2002) TEM-80, a novel inhibitor-resistant β-lactamase in a clinical isolate of Enterobacter cloacae. Antimicrob. Agents Chemother. 46: 1183-1189
73. Miro E., Navarro F., Mirelis B., Sabate M., Rivera A., Coll P. et al. (2002) Prevalence of clinical isolates of Escherichia coli producing inhibitor-resistant β-lactamases at a University Hospital in Barcelona, Spain, over a 3-year period. Antimicrob. Agents Chemother. 46: 3991-3994
74. Brinas L., Zarazaga M., Saenz Y., Ruiz-Larrea F. and Torres C. (2002) β-lactamases in ampicillin-resistant Escherichia coli isolates from foods, humans and healthy animals. Antimicrob. Agents Chemother. 46: 3156-3163
75. Meroueh S. O., Roblin P., Golemi D., Maveyraud L., Vakulenko S. B., Zhang Y. et al. (2002) Molecular dynamics at the root of expansion of function in the M69L inhibitor-resistant TEM β-lactamase from Escherichia coli. J. Am. Chem Soc. 124: 9422-9430
76. Poirel L., Gerome P., De Champs C., Stephanazzi J., Naas T. and Nordmann P. (2002) Integron-located oxa-32 gene cassette encoding an extended-spectrum variant of OXA-2 β-lactamase from Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 46: 566-569
77. Toleman M. A., Rolston K., Jones R. N. and Walsh T. R. (2003) Molecular and biochemical characterization of OXA-45, an extended-spectrum class 2d′ β-lactamase in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 47: 2859-2863
78. Franceschini N., Boschi L., Pollini S., Herman R., Perilli M., Galleni M. et al. (2001) Characterization of OXA-29 from Legionella (Fluoribacter) gormanii: molecular class D β-lactamase with unusual properties. Antimicrob. Agents Chemother. 45: 3509-3516
79. Aubert D., Poirel L., Chevalier J., Leotard S., Pages J. M. and Nordmann P. (2001) Oxacillinase-mediated resistance to cefepime and susceptibility to ceftazidime in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 45: 1615-1620
80. Dubois V., Arpin C., Quentin C., Texier-Maugein J., Poirel L. and Nordmann P. (2003) Decreased susceptibility to cefepime in a clinical strain of Escherichia coli related to plasmid- and integron-encoded OXA-30 β-lactamase. Antimicrob. Agents Chemother. 47: 2380-2381
81. Paterson D. L., Hujer K. M., Hujer A. M., Yeiser B., Bonomo M. D., Rice L. B. et al. (2003) Extended-spectrum β-lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV- and CTX-M-type β-lactamases. Antimicrob. Agents Chemother. 47: 3554-3560
82. Moland E. S., Black J. A., Hossain A., Hanson N. D., Thomson K. S. and Pottumarthy S. (2003) Discovery of CTX-M-like extended-spectrum β-lactamases in Escherichia coli isolates from five US States. Antimicrob. Agents Chemother. 47: 2382-2383
83. Edelstein M., Pimkin M., Palagin I., Edelstein I. and Stratchounski L. (2003) Prevalence and molecular epidemiology of CTX-M extended-spectrum β-Lactamase-producing Escherichia coli and Klebsiella pneumoniae in Russian hospitals. Antimicrob. Agents Chemother. 47: 3724-3732
84. Pagani L., Dell'Amico E., Migliavacca R., D'Andrea M. M., Giacobone E., Amicosante G. et al. (2003) Multiple CTX-M-type extended-spectrum β-lactamases in nosocomial isolates of Enterobacteriaceae from a hospital in northern Italy. J. Clin. Microbiol. 41: 4264-4269
85. Cao V., Lambert T., Nhu D. Q., Loan H. K., Hoang N. K., Arlet G. et al. (2002) Distribution of extended-spectrum β-lactamases in clinical isolates of Enterobacteriaceae in Vietnam. Antimicrob. Agents Chemother. 46: 3739-3743
86. Li C. R., Li Y. and Zhang P. A. (2003) Dissemination and spread of CTX-M extended-spectrum β-lactamases among clinical isolates of Klebsiella pneumoniae in central China. Int. J. Antimicrob. Agents 22: 521-525
87. Mushtaq S., Woodford N., Potz N. and Livermore D. M. (2003) Detection of CTX-M-15 extended-spectrum β-lactamase in the United Kingdom. J. Antimicrob. Chemother. 52: 528-529
88. Wang H., Kelkar S., Wu W., Chen M. and Quinn J. P. (2003) Clinical isolates of Enterobacteriaceae producing extended-spectrum β-lactamases: prevalence of CTX-M-3 at a hospital in China. Antimicrob. Agents Chemother. 47: 790-793
89. Yu W. L., Wu L. T., Pfaller M. A., Winokur P. L. and Jones R. N. (2003) Confirmation of extended-spectrum β-lactamase-producing Serratia marcescens: preliminary report from Taiwan. Diagn. Microbiol. Infect. Dis. 45: 221-224
90. Nagano N., Shibata N., Saitou Y., Nagano Y. and Arakawa Y. (2003) Nosocomial outbreak of infections by Proteus mirabilis that produces extended-spectrum CTX-M-2 type β-Lactamase. J. Clin. Microbiol. 41: 5530-5536
91. CTX-M-2 in Salmonella enterica serovar infantis. Antimicrob. Agents Chemother. 46: 2257-2261
92. Gierczynski R., Szych J., Rastawicki W. and Jagielski M. (2003) The molecular characterisation of the extended spectrum β-lactamase (ESBL) producing strain of Salmonella enterica serovar Mbandaka isolated in Poland. Acta Microbiol. Pol. 52: 183-190
93. Gierczynski R., Szych J., Cieslik A., Rastawicki W. and Jagielski M. (2003) The occurrence of the first two CTX-M-3 and TEM-1 producing isolates of Salmonella enterica serovar Oranienburg in Poland. Int. J. Antimicrob. Agents 21: 497-499
94. Su L. H., Chiu C. H., Chu C., Wang M. H., Chia J. H. and Wu T. L. (2003) In vivo acquisition of ceftriaxone resistance in Salmonella enterica serotype Anatum. Antimicrob. Agents Chemother. 47: 563-567
95. Petroni A., Corso A., Melano R., Cacace M. L., Bru A. M., Rossi A. et al. (2002) Plasmidic extended-spectrum β-lactamases in Vibrio cholerae O1 El Tor isolates in Argentina. Antimicrob. Agents Chemother. 46: 1462-1468
96. Acikgoz Z. C., Gulay Z., Bicmen M., Gocer S. and Gamberzade S. (2003) CTX-M-3 extended-spectrum β-lactamase in a Shigella sonnei clinical isolate: first report from Turkey. Scand. J. Infect. Dis. 35: 503-505
97. Humeniuk C., Arlet G., Gautier V., Grimont P., Labia R. and Philippon A. (2002) β-lactamases of Kluyvera ascorbata, probable progenitors of some plasmid-encoded CTX-M types. Antimicrob. Agents Chemother. 46: 3045-3049
98. CTX-M-2 is located in an unusual class 1 integron (In35) which includes Orf513. Antimicrob. Agents Chemother. 46: 2303-2306
99. Saladin M., Cao V. T., Lambert T., Donay J. L., Herrmann J. L., Ould-Hocine Z. et al. (2002) Diversity of CTX-M β-lactamases and their promoter regions from Enterobacteriaceae isolated in three Parisian hospitals. FEMS Microbiol. Lett. 209: 161-168
100. Poirel L., Kampfer P. and Nordmann P. (2002) Chromosome-encoded Ambler class A β-lactamase of Kluyvera georgiana, a probable progenitor of a subgroup of CTX-M extended-spectrum β-lactamases. Antimicrob. Agents Chemother. 46: 4038-4040
101. Yong D., Shin J. H., Kim S., Lim Y., Yum J. H., Lee K. et al. (2003) High prevalence of PER-1 extended-spectrum β-lactamase-producing Acinetobacter spp. in Korea. Antimicrob. Agents Chemother. 47: 1749-1751
102. Pagani L., Migliavacca R., Pallecchi L., Matti C., Giacobone E., Amicosante G., Romero E. et al. (2002) Emerging extended-spectrum β-lactamases in Proteus mirabilis. J. Clin. Microbiol. 40: 1549-1552
103. Kwon N. Y., Kim J. D. and Pai H. J. (2002) The resistance mechanisms of β-lactam antimicrobials in clinical isolates of Acinetobacter baumannii. Korean J. Intern. Med. 17: 94-99
104. Girlich D., Poirel L., Leelaporn A., Karim A., Tribuddharat C., Fennewald M. et al. (2001) Molecular epidemiology of the integron-located VEB-1 extended-spectrum β-lactamase in nosocomial enterobacterial isolates in Bangkok, Thailand. J. Clin. Microbiol. 39: 175-182
105. Naas T., Mikami Y., Imai T., Poirel L. and Nordmann P. (2001) Characterization of In53, a class 1 plasmid- and composite transposon-located integron of Escherichia coli which carries an unusual array of gene cassettes. J. Bacteriol. 183: 235-249
106. Aubert D., Naas T. and Nordmann P. (2003) IS1999 increases expression of the extended-spectrum β-lactamase VEB-1 in Pseudomonas aeruginosa. J. Bacteriol. 185: 5314-5319
107. Girlich D., Naas T., Leelaporn A., Poirel L., Fennewald M. and Nordmann P. (2002) Nosocomial spread of the integron-located veb-1-like cassette encoding an extended-spectrum β-lactamase in Pseudomonas aeruginosa in Thailand. Clin. Infect. Dis. 34: 603-611
108. Poirel L., Menuteau O., Agoli N., Cattoen C. and Nordmann P. (2003) Outbreak of extended-spectrum P-lactamase VEB-1-producing isolates of Acinetobacter baumannii in a French hospital. J. Clin. Microbiol. 41: 3542-3547
109. Naas T., Benaoudia F., Massuard S. and Nordmann P. (2000) Integron-located VEB-1 extended-spectrum β-lactamase gene in a Proteus mirabilis clinical isolate from Vietnam. J. Antimicrob. Chemother. 46: 703-711
110. Matsumoto Y. and Inoue M. (1999) Characterization of SFO-1, a plasmid-mediated inducible class A β-lactamase from Enterobacter cloacae. Antimicrob. Agents Chemother. 43: 307-313
111. Bonnet R., Sampaio J. L., Chanal C., Sirot D., De Champs C., Viallard J. L. et al. (2000) A novel class A extended-spectrum β-lactamase (BES-1) in Serratia marcescens isolated in Brazil. Antimicrob. Agents Chemother. 44: 3061-3068
112. Morin A. S., Poirel L., Mory F., Labia R. and Nordmann P. (2002) Biochemical-genetic analysis and distribution of DES-1, an Ambler class A extended-spectrum β-lactamase from Desulfovibrio desulfuricans. Antimicrob. Agents Chemother. 46: 3215-3222
113. Giakkoupi P., Tzouvelekis L. S., Tsakris A., Loukova V., Sofianou D. and Tzelepi E. (2000) IBC-1, a novel integron-associated class A β-lactamase with extended-spectrum properties produced by an Enterobacter cloacae clinical strain. Antimicrob. Agents Chemother. 44: 2247-2253
114. IBC-1. FEMS Microbiol. Lett. 225: 149-153
115. Vourli S., Tzouvelekis L. S., Tzelepi E., Kartali G., Kontopoulou C., Sofianou D. et al. (2003) Characterization of Klebsiella pneumoniae clinical strains producing a rare extended-spectrum β-lactamase (IBC-1). Int. J. Antimicrob. Agents 21: 495-497
116. Tzelepi E., Magana C., Platsouka E., Sofianou D., Paniara O., Legakis N. J. et al. (2003) Extended-spectrum β-lactamase types in Klebsiella pneumoniae and Escherichia coli in two Greek hospitals. Int. J. Antimicrob. Agents 21: 285-288
117. Mavroidi A., Tzelepi E., Tsakris A., Miriagou V., Sofianou D. and Tzouvelekis L. S. (2001) An integron-associated β-lactamase (IBC-2) from Pseudomonas aeruginosa is a variant of the extended-spectrum β-lactamase IBC-1. J. Antimicrob. Chemother. 48: 627-630
118. Poirel L., Le T., I, Naas T., Karim A. and Nordmann P. (2000) Biochemical sequence analyses of GES-1, a novel class A extended-spectrum β-lactamase, and the class 1 integron In52 from Klebsiella pneumoniae. Antimicrob. Agents Chemother. 44: 622-632
119. Duarte A., Boavida F., Grosso F., Correia M., Lito L. M., Cristino J. M. et al. (2003) Outbreak of GES-1 β-lactamase-producing multidrug-resistant Klebsiella pneumoniae in a university hospital in Lisbon, Portugal. Antimicrob. Agents Chemother. 47: 1481-1482
120. Correia M., Boavida F., Grosso F., Salgado M. J., Lito L. M., Cristino J. M. et al. (2003) Molecular characterization of a new class 3 integron in Klebsiella pneumoniae. Antimicrob. Agents Chemother. 47: 2838-2843
121. GES-1 and a fused product of aac3-Ib/aac6′-Ib′ gene cassettes in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 46: 638-645
122. Poirel L., Weldhagen G. F., De Champs C. and Nordmann P. (2002) A nosocomial outbreak of Pseudomonas aeruginosa isolates expressing the extended-spectrum β-lactamase GES-2 in South Africa. J. Antimicrob. Chemother. 49: 561-565
123. ROB-1 mutations in hypermutagenic ampC Escherichia coli conferring resistance to cefotaxime and β-lactamase inhibitors and increased susceptibility to cefaclor. Antimicrob. Agents Chemother. 47: 2551-2557
124. Tribuddharat C., Moore R. A., Baker P. and Woods D. E. (2003) Burkholderia pseudomallei class A β-lactamase mutations that confer selective resistance against ceftazidime or clavulanic acid inhibition. Antimicrob. Agents Chemother. 47: 2082-2087
125. Niumsup P. and Wuthiekanun V. (2002) Cloning of the class D β-lactamase gene from Burkholderia pseudomallei and studies on its expression in ceftazidime-susceptible and -resistant strains. J. Antimicrob. Chemother. 50: 445-455
126. OXY-2 family of chromosomal Klebsiella enzymes. Antimicrob. Agents Chemother. 46: 2056-2057
127. Mammeri H., Poirel L. and Nordmann P. (2003) In vivo selection of a chromosomally encoded β-lactamase variant conferring ceftazidime resistance in Klebsiella oxytoca. Antimicrob. Agents Chemother. 47: 3739-3742
128. Zhou Z., Li L., Yu Y. and Ma Y. (2003) The status of drug resistance and ampC gene expression in Enterobacter cloacae. Chin. Med. J. (Engl.) 116: 1244-1247
129. Procop G. W., Tuohy M. J., Wilson D. A., Williams D., Hadziyannis E. and Hall G. S. (2003) Cross-class resistance to non-β-lactam antimicrobials in extended-spectrum β-lactamase-producing Klebsiella pneumoniae. Am. J. Clin. Pathol. 120: 265-267
130. Jones R. N., Biedenbach D. J. and Gales A. C. (2003) Sustained activity and spectrum of selected extended-spectrum β-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA, 1997-2000). Int. J. Antimicrob. Agents 21: 1-7
131. Villa L., Pezzella C., Tosini F., Visca P., Petrucca A. and Carattoli A. (2000) Multiple-antibiotic resistance mediated by structurally related IncL/M plasmids carrying an extended-spectrum β-lactamase gene and a class 1 integron. Antimicrob. Agents Chemother. 44: 2911-2914
132. Tolun V., Kucukbasmaci O., Torumkuney-Akbulut D., Catal C., Ang-Kucuker M. and Ang O. (2004) Relationship between ciprofloxacin resistance and extended-spectrum β-lactamase production in Escherichia coli and Klebsiella pneumoniae strains. Clin. Microbiol. Infect. 10: 72-75
133. Bouza E. and Cercenado E. (2002) Klebsiella and Enterobacter: antibiotic resistance and treatment implications. Semin. Respir. Infect. 17: 215-230
134. Gal Z., Szabo D., Kovacs P., Hernadi F., Toth-Martinez B. and Rozgonyi F. (2000) β-lactam susceptibility patterns and investigation of cephalosporin hydrolysing β-lactamases of Gram-negative extraintestinal clinical isolates. Int. J. Antimicrob. Agents 16: 395-400
135. Coudron P. E., Hanson N. D. and Climo M. W. (2003) Occurrence of extended-spectrum and AmpC β-lactamases in bloodstream isolates of Klebsiella pneumoniae: isolates harbor plasmid-mediated FOX-5 and ACT-1 AmpC β-lactamases. J. Clin. Microbiol. 41: 772-777
136. Barnaud G., Labia R., Raskine L., Sanson-Le Pors M. J., Philippon A. and Arlet G. (2001) Extension of resistance to cefepime and cefpirome associated to a six amino acid deletion in the H-10 helix of the cephalosporinase of an Enterobacter cloacae clinical isolate. FEMS Microbiol. Lett. 195: 185-190
137. Vakulenko S. B., Golemi D., Geryk B., Suvorov M., Knox J. R., Mobashery S. et al. (2002) Mutational replacement of Leu-293 in the class C Enterobacter cloacae P99 β-lactamase confers increased MIC of cefepime. Antimicrob. Agents Chemother. 46: 1966-1970
138. Barnaud G., Benzerara Y., Gravisse J., Raskine L., Sanson-Le Pors M. J., Labia R. et al. (2004) Selection during cefepime treatment of a new cephalosporinase variant with extended-spectrum resistance to cefepime in an Enterobacter aerogenes clinical isolate. Antimicrob. Agents Chemother. 48: 1040-1042
139. Mammeri H., Poirel L., Bemer P., Drugeon H. and Nordmann P. (2004) Resistance to cefepime and cefpirome due to a 4-amino-acid deletion in the chromosome-encoded AmpC β-lactamase of a Serratia marcescens clinical isolate. Antimicrob. Agents Chemother. 48: 716-720
140. Armand-Lefevre L., Leflon-Guibout V., Bredin J., Barguellil F., Amor A., Pages J. M. et al. (2003) Imipenem resistance in Salmonella enterica serovar Wien related to porin loss and CMY-4 β-lactamase production. Antimicrob. Agents Chemother. 47: 1165-1168
141. Cao V. T., Arlet G., Ericsson B. M., Tammelin A., Courvalin P. and Lambert T. (2000) Emergence of imipenem resistance in Klebsiella pneumoniae owing to combination of plasmid-mediated CMY-4 and permeability alteration. J. Antimicrob. Chemother. 46: 895-900
142. Quale J., Bratu S., Landman D. and Heddurshetti R. (2003) Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic in New York City. Clin. Infect. Dis. 37: 214-220
143. Stock I., Sherwood K. J. and Wiedemann B. (2003) Natural antibiotic susceptibility of Ewingella americana strains. J. Chemother. 15: 428-441
144. Stock I., Burak S., Sherwood K. J., Gruger T. and Wiedemann B. (2003) Natural antimicrobial susceptibilities of strains of 'unusual' Serratia species: S. ficaria, S. fonticola, S. odorifera, S. plymuthica and S. rubidaea. J. Antimicrob. Chemother. 51: 865-885
145. Stock I., Henrichfreise B. and Wiedemann B. (2002) Natural antibiotic
146. Stock I. and Wiedemann B. (2003) Natural antimicrobial susceptibilities and biochemical profiles of Yersinia enterocolitica-like strains: Y. frederiksenii, Y. intermedia, Y. kristensenii and Y. rohdei. FEMS Immunol. Med. Microbiol. 38: 139-152
147. Nadjar D., Labia R., Cerceau C., Bizet C., Philippon A. and Arlet G. (2001) Molecular characterization of chromosomal class C β-lactamase and its regulatory gene in Ochrobactrum anthropi. Antimicrob. Agents Chemother. 45: 2324-2330
148. Jones R. N. (1998) Important and emerging β-lactamase-mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn. Microbiol. Infect. Dis. 31: 461-466
149. Wouters J., Fonze E., Vermeire M., Frere J. M. and Charlier P. (2003) Crystal structure of Enterobacter cloacae 908R class C β-lactamase bound to iodo-acetamido-phenyl boronic acid, a transition-state analogue. Cell. Mol. Life Sci. 60: 1764-1773
150. Nukaga M., Kumar S., Nukaga K., Pratt R. F. and Knox J. R. (2004) Hydrolysis of third-generation cephalosporins by class C β-lactamases. Structures of a transition state analog of cefotoxamine in wild-type and extended spectrum enzymes. J. Biol. Chem. 279: 9344-9352
151. Hanson N. D. and Sanders C. C. (1999) Regulation of inducible AmpC β-lactamase expression among Enterobacteriaceae. Curr. Pharm. Des. 5: 881-894
152. Kuga A., Okamoto R. and Inoue M. (2000) ampR gene mutations that greatly increase class C β-lactamase activity in Enterobacter cloacae. Antimicrob. Agents Chemother. 44: 561-567
153. Petrosino J. F., Pendleton A. R., Weiner J. H. and Rosenberg S. M. (2002) Chromosomal system for studying AmpC-mediated β-lactam resistance mutation in Escherichia coli. Antimicrob. Agents Chemother. 46: 1535-1539
154. Bagge N., Ciofu O., Hentzer M., Campbell J. I., Givskov M. and Hoiby N. (2002) Constitutive high expression of chromosomal β-lactamase in Pseudomonas aeruginosa caused by a new insertion sequence (IS1669) located in ampD. Antimicrob. Agents Chemother. 46: 3406-3411
155. Siu L. K., Lu P. L., Chen J. Y., Lin F. M. and Chang S. C. (2003) High-level expression of ampC β-lactamase due to insertion of nucleotides between -10 and -35 promoter sequences in Escherichia coli clinical isolates: cases not responsive to extended-spectrum-cephalosporin treatment. Antimicrob. Agents Chemother. 47: 2138-2144
156. Hirakawa H., Nishino K., Yamada J., Hirata T. and Yamaguchi A. (2003) β-lactam resistance modulated by the overexpression of response regulators of two-component signal transduction systems in Escherichia coli. J. Antimicrob. Chemother. 52: 576-582
157. Corvec S., Caroff N., Espaze E., Giraudeau C., Drugeon H. and Reynaud A. (2003) AmpC cephalosporinase hyperproduction in Acinetobacter baumannii clinical strains. J. Antimicrob. Chemother. 52: 629-635
158. Segal H., Nelson E. C. and Elisha B. G. (2004) Genetic environment and transcription of ampC in an Acinetobacter baumannii clinical isolate. Antimicrob. Agents Chemother. 48: 612-614
159. Pfaller M. A. and Jones R. N. (2002) Antimicrobial susceptibility of inducible AmpC β-lactamase-producing Enterobacteriaceae from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme, Europe 1997-2000. Int. J. Antimicrob. Agents 19: 383-388
160. Boyle R. J., Curtis N., Kelly N., Garland S. M. and Carapetis J. R. (2002) Clinical implications of inducible β-lactamase activity in Gram-negative bacteremia in children. Pediatr. Infect. Dis. J 21: 935-940
161. Conceicao T., Faria N., Lito L., Melo C. J., Salgado M. J. and Duarte A. (2004) Diversity of chromosomal AmpC β-lactamases from Enterobacter cloacae isolates in a Portuguese hospital. FEMS Microbiol. Lett. 230: 197-202
162. Lister P. D. (2002) Chromosomally-encoded resistance mechanisms of Pseudomonas aeruginosa: therapeutic implications. Am. J. Pharmacogenomics. 2: 235-243
163. Shahid M., Malik A. and Sheeba. (2003) Multidrug-resistant Pseudomonas aeruginosa strains harbouring R-plasmids and AmpC β-lactamases isolated from hospitalised burn patients in a tertiary care hospital of North India. FEMS Microbiol. Lett. 228: 181-186
164. Cavallo J. D., Plesiat P., Couetdic G., Leblanc F. and Fabre R. (2002) Mechanisms of β-lactam resistance in Pseudomonas aeruginosa: prevalence of OprM-overproducing strains in a French multicentre study (1997) J. Antimicrob. Chemother. 50: 1039-1043
165. Beceiro A., Dominguez L., Ribera A., Vila J., Molina F., Villanueva R. et al. (2004) Molecular characterization of the gene encoding a new AmpC β-lactamase in a clinical strain of Acinetobacter genomic species 3. Antimicrob. Agents Chemother. 48: 1374-1378
166. Steward C. D., Rasheed J. K., Hubert S. K., Biddle J. W., Raney P. M., Anderson G. J. et al. (2001) Characterization of clinical isolates of Klebsiella pneumoniae from 19 laboratories using the National Committee for Clinical Laboratory Standards extended-spectrum β-lactamase detection methods. J. Clin. Microbiol. 39: 2864-2872
167. Alvarez M., Tran J. H., Chow N. and Jacoby G. A. (2004) Epidemiology of conjugative plasmid-mediated AmpC β-actamases in the United States. Antimicrob. Agents Chemother. 48: 533-537
168. Reisbig M. D., Hossain A. and Hanson N. D. (2003) Factors influencing gene expression and resistance for Gram-negative organisms expressing plasmid-encoded ampC genes of Enterobacter origin. J. Antimicrob. Chemother. 51: 1141-1151
169. Rodriguez-Martinez J. M., Pascual A., Garcia I. and Martinez-Martinez L. (2003) Detection of the plasmid-mediated quinolone resistance determinant qnr among clinical isolates of Klebsiella pneumoniae producing AmpC-type β-lactamase. J. Antimicrob. Chemother. 52: 703-706
170. Zhao S., Qaiyumi S., Friedman S., Singh R., Foley S. L., White D. G. et al. (2003) Characterization of Salmonella enterica serotype newport isolated from humans and food animals. J. Clin. Microbiol. 41: 5366-5371
171. DHA-1 gene and its regulator gene ampR, originated from Morganella morganii. Antimicrob. Agents Chemother. 44: 222-225
172. Winokur P. L., Brueggemann A., DeSalvo D. L., Hoffmann L., Apley M. D., Uhlenhopp E. K. et al. (2000) Animal and human multidrug-resistant, cephalosporin-resistant salmonella isolates expressing a plasmid-mediated CMY-2 AmpC β-lactamase. Antimicrob. Agents Chemother. 44: 2777-2783
173. Wu S. W., Dornbusch K., Kronvall G. and Norgren M. (1999) Characterization and nucleotide sequence of a Klebsiella oxytoca cryptic plasmid encoding a CMY-type β-lactamase: confirmation that the plasmid-mediated cephamycinase originated from the Citrobacter freundii AmpC β-lactamase. Antimicrob. Agents Chemother. 43: 1350-1357
174. Barlow M. and Hall B. G. (2002) Origin and evolution of the AmpC β-lactamases of Citrobacter freundii. Antimicrob. Agents Chemother. 46: 1190-1198
175. Hanson N. D., Moland E. S., Hossain A., Neville S. A., Gosbell I. B. and Thomson K. S. (2002) Unusual Salmonella enterica serotype Typhimurium isolate producing CMY-7, SHV-9 and OXA-30 β-lactamases. J. Antimicrob. Chemother. 49: 1011-1014
176. Decre D., Verdet C., Raskine L., Blanchard H., Burghoffer B., Philippon A. et al. (2002) Characterization of CMY-type β-lactamases in clinical strains of Proteus mirabilis and Klebsiella pneumoniae isolated in four hospitals in the Paris area. J. Antimicrob. Chemother. 50: 681-688
177. Nakano R., Okamoto R., Nakano Y., Kaneko K., Okitsu N., Hosaka Y. et al. (2004) CFE-1, a Novel Plasmid-Encoded AmpC β-Lactamase with an with an ampR Gene Originating from Citrobacter freundii. Antimicrob. Agents Chemother. 48: 1151-1158
178. Pitout J. D., Reisbig M. D., Mulvey M., Chui L., Louie M., Crowe L. et al. (2003) Association between handling of pet treats and infection with Salmonella enterica serotype new-port expressing the AmpC β-lactamase, CMY-2. J. Clin. Microbiol. 41: 4578-4582
179. Navarro F., Perez-Trallero E., Marimon J. M., Aliaga R., Gomariz M. and Mirelis B. (2001) CMY-2-producing Salmonella enterica, Klebsiella pneumoniae, Klebsiella oxytoca, Proteus mirabilis and Escherichia coli strains isolated in Spain (October 1999-December 2000). J. Antimicrob. Chemother. 48: 383-389
180. Yan J. J., Ko W. C., Chiu C. H., Tsai S. H., Wu H. M. and Wu J. J. (2003) Emergence of ceftriaxone-resistant Salmonella isolates and rapid spread of plasmid-encoded CMY-2-like cephalosporinase, Taiwan. Emerg. Infect. Dis. 9: 323-328
181. Hoyen C. M., Hujer A. M., Hujer K. M., Marshall S. H., Carias L., Toltzis P. et al. (2002) A clinical strain of Escherichia coli possessing CMY-2 plasmid-mediated amp C β-lactamase: an emerging concern in pediatrics? Microb. Drug Resist. 8: 329-333
182. Odeh R., Kelkar S., Hujer A. M., Bonomo R. A., Schreckenberger P. C. and Quinn J. P. (2002) Broad resistance due to plasmid-mediated AmpC P-lactamases in clinical isolates of Escherichia coli. Clin. Infect. Dis.. 35: 140-145
183. Fosse T., Giraud-Morin C., Madinier I. and Labia R. (2003) Sequence analysis and biochemical characterisation of chromosomal CAV-1 (Aeromonas caviae), the parental cephalosporinase of plasmid-mediated AmpC 'FOX' cluster. FEMS Microbiol. Lett. 222. 93-98
184. Doi Y., Shibata N., Shibayama K., Kamachi K., Kurokawa H., Yokoyama K. et al. (2002) Characterization of a novel plasmid-mediated cephalosporinase (CW-9) and its genetic environment in an Escherichia coli clinical isolate. Antimicrob. Agents Chemother. 46: 2427-2434
185. Queenan A. M., Jenkins S. and Bush K. (2001) Cloning and biochemical characterization of FOX-5, an AmpC-type plasmid-encoded β-lactamase from a New York City Klebsiella pneumoniae clinical isolate. Antimicrob. Agents Chemother. 45: 3189-3194
186. Yong D., Park R., Yum J. H., Lee K., Choi E. C. and Chong Y. (2002) Further modification of the Hodge test to screen AmpC β-lactamase (CMY-1)-producing strains of Escherichia coli and Klebsiella pneumoniae. J. Microbiol. Methods 51: 407-410
187. CMY-11, an AmpC-type plasmid-mediated β-lactamase gene in a Korean clinical isolate of Escherichia coli. J. Antimicrob. Chemother. 49: 269-273
188. Lee S. H., Jeong S. H. and Park Y. M. (2003) Characterization of blaCMY-10 a novel, plasmid-encoded AmpC-type β-lactamase gene in a clinical isolate of Enterobacter aerogenes. J. Appl. Microbiol. 95: 744-752
189. Raskine L., Borrel I., Barnaud G., Boyer S., Hanau-Bercot B., Gravisse J. et al. (2002) Novel plasmid-encoded class C β-lactamase (MOX-2) in Klebsiella pneumoniae from Greece. Antimicrob. Agents Chemother. 46: 2262-2265
190. Rottman M., Benzerara Y., Hanau-Bercot B., Bizet C., Philippon A. and Arlet G. (2002) Chromosomal ampC genes in Enterobacter species other than Enterobacter cloacae, and ancestral association of the ACT-1 plasmid-encoded cephalosporinase to Enterobacter asburiae. FEMS Microbiol. Lett. 210: 87-92
191. Reisbig M. D. and Hanson N. D. (2002) The ACT-1 plasmid-encoded AmpC β-lactamase is inducible: detection in a complex β-lactamase background. J. Antimicrob. Chemother. 49: 557-560
192. Yan J. J., Ko W. C., Jung Y. C., Chuang C. L. and Wu J. J. (2002) Emergence of Klebsiella pneumoniae isolates producing inducible DHA-1 β-lactamase in a university hospital in Taiwan. J. Clin. Microbiol. 40: 3121-3126
193. Barnaud G., Arlet G., Verdet C., Gaillot O., Lagrange P. H. and Philippon A. (1998) Salmonella enteritidis: AmpC plasmid-mediated inducible β-lactamase (DHA-1) with an ampR gene from Morganella morganii. Antimicrob. Agents Chemother. 42: 2352-2358
194. Poirel L., Guibert M., Girlich D., Naas T. and Nordmann P. (1999) Cloning, sequence analyses, expression and distribution of ampC-ampR from Morganella morganii clinical isolates. Antimicrob. Agents Chemother. 43: 769-776
195. Fortineau N., Poirel L. and Nordmann P. (2001) Plasmid-mediated and inducible cephalosporinase DHA-2 from Klebsiella pneumoniae. J. Antimicrob. Chemother. 47: 207-210
196. Makanera A., Arlet G., Gautier V. and Manai M. (2003) Molecular epidemiology and characterization of plasmid-encoded β-lactamases produced by Tunisian clinical isolates of Salmonella enterica serotype Mbandaka resistant to broad-spectrum cephalosporins. J. Clin. Microbiol. 41: 2940-2945
197. Girlich D., Karim A., Spicq C. and Nordmann P. (2000) Plasmid-mediated cephalosporinase ACC-1 in clinical isolates of Proteus mirabilis and Escherichia coli. Eur. J. Clin. Microbiol. Infect. Dis. 19: 893-895
198. Girlich D., Naas T., Bellais S., Poirel L., Karim A. and Nordmann P. (2000) Biochemical-genetic characterization and regulation of expression of an ACC-1-like chromosome-borne cephalosporinase from Hafnia alvei. Antimicrob. Agents Chemother. 44: 1470-1478
199. Nadjar D., Rouveau M., Verdet C., Donay L., Herrmann J., Lagrange P. H. et al. (2000) Outbreak of Klebsiella pneumoniae producing transferable AmpC-type β-lactamase (ACC-1) originating from Hafnia alvei. FEMS Microbiol. Lett. 187: 35-40
200. Bonfiglio G., Russo G. and Nicoletti G. (2002) Recent developments in carbapenems. Expert. Opin. Investig. Drugs 11: 529-544
201. Livermore D. M. (2002) The impact of carbapenemases on antimicrobial development and therapy. Curr. Opin. Investig. Drugs 3: 218-224
202. Stunt R. A., Amyes A. K., Thomson C. J., Payne D. J. and Amyes S. G. (1998) The production of a novel carbapenem-hydrolysing β-lactamase in Aeromonas veronii biovar sobria, and its association with imipenem resistance. J. Antimicrob. Chemother. 42: 835-836
203. Swaren P., Maveyraud L., Raquet X., Cabantous S., Duez C., Pedelacq J. D. et al. (1998) X-ray analysis of the NMC-A β-lactamase at 1.64-A resolution, a class A carbapenemase with broad substrate specificity. J. Biol. Chem. 273: 26714-26721
204. Yigit H., Queenan A. M., Rasheed J. K., Biddle J. W., Domenech-Sanchez A., Alberti S. et al. (2003) Carbapenem-resistant strain of Klebsiella oxytoca harboring carbapenem-hydrolyzing β-lactamase KPC-2. Antimicrob. Agents Chemother. 47: 3881-3889
205. Smith M. E., Hanson N. D., Herrera V. L., Black J. A., Lockhart T. J., Hossain A. et al. (2003) Plasmid-mediated, carbapenem-hydrolysing β-lactamase, KPC-2, in Klebsiella pneumoniae isolates. J. Antimicrob. Chemother. 51: 711-714
206. Miriagou V., Tzouvelekis L. S., Rossiter S., Tzelepi E., Angulo F. J. and Whichard J. M. (2003) Imipenem resistance in a Salmonella clinical strain due to plasmid-mediated class A carbapenemase KPC-2. Antimicrob. Agents Chemother. 47: 1297-1300
207. Galleni M., Lamotte-Brasseur J., Rossolini G. M., Spencer J., Dideberg O. and Frere J. M. (2001) Standard numbering scheme for class B β-lactamases. Antimicrob. Agents Chemother. 45: 660-663
208. Rasmussen B. A. and Bush K. (1997) Carbapenem-hydrolyzing β-lactamases. Antimicrob. Agents Chemother. 41: 223-232
209. Kato N., Yamazoe K., Han C. G. and Ohtsubo E. (2003) New insertion sequence elements in the upstream region of cfiA in imipenem-resistant Bacteroides fragilis strains. Antimicrob. Agents Chemother. 47: 979-985
210. Iyobe S., Kusadokoro H., Takahashi A., Yomoda S., Okubo T., Nakamura A. et al. (2002) Detection of a variant metallo-β-lactamase, IMP-10, from two unrelated strains of Pseudomonas aeruginosa and an Alcaligenes xylosoxidans strain. Antimicrob. Agents Chemother. 46: 2014-2016
211. Docquier J. D., Riccio M. L., Mugnaioli C., Luzzaro F., Endimiani A., Toniolo A. et al. (2003) IMP-12, a new plasmid-encoded metallo-β-lactamase from a Pseudomonas putida clinical isolate. Antimicrob. Agents Chemother. 47: 1522-1528
212. Toleman M. A., Biedenbach D., Bennett D., Jones R. N. and Walsh T. R. (2003) Genetic characterization of a novel metallo-β-lactamase gene, blaIMP-13, harboured by a novel Tn5051-type transposon disseminating carbapenemase genes in Europe: report from the SENTRY worldwide antimicrobial surveillance programme. J. Antimicrob. Chemother. 52: 583-590
213. Ho S. E., Subramaniam G., Palasubramaniam S. and Navaratnam P. (2002) Carbapenem-resistant Pseudomonas aeruginosa in Malaysia producing IMP-7 β-lactamase. Antimicrob. Agents Chemother. 46: 3286-3287
214. Lee K., Lee W. G., Uh Y., Ha G. Y., Cho J. and Chong Y. (2003) VIM- and IMP-type metallo-β-lactamase-producing Pseudomonas spp. and Acinetobacter spp. in Korean hospitals. Emerg. Infect. Dis. 9: 868-871
215. Oh E. J., Lee S., Park Y. J., Park J. J., Park K., Kim S. I. et al. (2003) Prevalence of metallo-β-lactamase among Pseudomonas aeruginosa and Acinetobacter baumannii in a Korean university hospital and comparison of screening methods for detecting metallo-β-lactamase. J. Microbiol. Methods 54: 411-418
216. IMP-7. Antimicrob. Agents Chemother. 46: 255-258
217. Shibata N., Doi Y., Yamane K., Yagi T., Kurokawa H., Shibayama K. et al. (2003) PCR typing of genetic determinants for metallo-β-lactamases and integrases carried by Gram-negative bacteria isolated in Japan, with focus on the class 3 integron. J. Clin. Microbiol. 41: 5407-5413
218. IMP-5, a new integron-borne metallo-β-lactamase gene from an Acinetobacter baumannii nosocomial isolate in Portugal. FEMS Microbiol. Lett. 215: 33-39
219. Tysall L., Stockdale M. W., Chadwick P. R., Palepou M. F., Towner K. J., Livermore D. M. et al. (2002) IMP-1 carbapenemase detected in an Acinetobacter clinical isolate from the UK. J. Antimicrob. Chemother. 49: 217-218
220. IMP in a hospital in Japan. J. Clin. Microbiol. 41: 4246-4251
221. IMP-8 in a university medical center in Taiwan. J. Clin. Microbiol. 39: 4433-4439
222. 222 Yan J. J., Ko W. C., Chuang C. L. and Wu J. J. (2002) Metallo-β-lactamase-producing Enterobacteriaceae isolates in a university hospital in Taiwan: prevalence of IMP-8 in Enterobacter cloacae and first identification of VIM-2 in Citrobacter freundii. J. Antimicrob. Chemother. 50: 503-511
223. Yan J. J., Hsueh P. R., Ko W. C., Luh K. T., Tsai S. H., Wu H. M. et al. (2001) Metallo-β-lactamases in clinical Pseudomonas isolates in Taiwan and identification of VIM-3, a novel variant of the VIM-2 enzyme. Antimicrob. Agents Chemother. 45: 2224-2228
224. VIM-1 in a clinical strain of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 46: 4026-4028
225. VIM-7, an evolutionarily distinct metallo-βlactamase gene in a Pseudomonas aeruginosa isolate from the United States. Antimicrob. Agents Chemother. 48: 329-332
226. Giske C. G., Rylander M. and Kronvall G. (2003) VIM-4 in a carbapenem-resistant strain of Pseudomonas aeruginosa isolated in Sweden. Antimicrob. Agents Chemother. 47: 3034-3035
227. VIM-4 gene cassette isolated from hospitalized children in Poland (1998-2001). J. Antimicrob. Chemother. 53: 451-456
228. Giakkoupi P., Petrikkos G., Tzouvelekis L. S., Tsonas S., Legakis N. J. and Vatopoulos A. C. (2003) Spread of integron-associated VIM-type metallo-β-lactamase genes among imipenem-nonsusceptible Pseudomonas aeruginosa strains in Greek hospitals. J. Clin. Microbiol. 41: 822-825
229. VIM-2 cassette-containing novel integrons in metallo-β- lactamase-producing Pseudomonas aeruginosa and Pseudomonas putida isolates disseminated in a Korean hospital. Antimicrob. Agents Chemother. 46: 1053-1058
230. VIM-2 in Pseudomonas aeruginosa clinical strains isolated in Japan. Antimicrob. Agents Chemother. 48: 626-628
231. Cardoso O., Leitao R., Figueiredo A., Sousa J. C., Duarte A. and Peixe L. V. (2002) Metallo-β-lactamase VIM-2 in clinical isolates of Pseudomonas aeruginosa from Portugal. Microb. Drug Resist. 8: 93-97
232. Lombardi G., Luzzaro F., Docquier J. D., Riccio M. L., Perilli M., Coli A. et al. (2002) Nosocomial infections caused by multidrug-resistant isolates of Pseudomonas putida producing VIM-1 metallo-β-lactamase. J. Clin. Microbiol. 40: 4051-4055
233. VIM-2 gene cassettes. J. Antimicrob. Chemother. 49: 837-840
234. Jeong S. H., Lee K., Chong Y., Yum J. H., Lee S. H., Choi H. J. et al. (2003) Characterization of a new integron containing VIM-2, a metallo-β-lactamase gene cassette, in a clinical isolate of Enterobacter cloacae. J. Antimicrob. Chemother. 51: 397-400
235. Luzzaro F., Docquier J. D., Colinon C., Endimiani A., Lombardi G., Amicosante G. et al. (2004) Emergence in Klebsiella pneumoniae and Enterobacter cloacae clinical isolates of the VIM-4 metallo-β-actamase encoded by a conjugative plasmid. Antimicrob. Agents Chemother. 48: 648-650
236. Yum J. H., Yong D., Lee K., Kim H. S. and Chong Y. (2002) A new integron carrying VIM-2 metallo-β-lactamase gene cassette in a Serratia marcescens isolate. Diagn. Microbiol. Infect. Dis. 42: 217-219
237. Giakkoupi P., Xanthaki A., Kanelopoulou M., Vlahaki A., Miriagou V., Kontou S. et al. (2003) VIM-1 metallo-β-lactamase-producing Klebsiella pneumoniae strains in Greek hospitals. J. Clin. Microbiol. 41: 3893-3896
238. Miriagou V., Tzelepi E., Gianneli D. and Tzouvelekis L. S. (2003) Escherichia coli with a self-transferable, multiresistant plasmid coding for metallo-β-lactamase VIM-1. Antimicrob. Agents Chemother. 47: 395-397
239. Toleman M. A., Simm A. M., Murphy T. A., Gales A. C., Biedenbach D. J., Jones R. N. et al. (2002) Molecular characterization of SPM-1, a novel metallo-β-lactamase isolated in Latin America: report from the SENTRY antimicrobial surveillance programme. J. Antimicrob. Chemother. 50: 673-679
240. Murphy T. A., Simm A. M., Toleman M. A., Jones R. N. and Walsh T. R. (2003) Biochemical characterization of the acquired metallo-β-lactamase SPM-1 from Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 47: 582-587
241. Gales A. C., Menezes L. C., Silbert S. and Sader H. S. (2003) Dissemination in distinct Brazilian regions of an epidemic carbapenem-resistant Pseudomonas aeruginosa producing SPM metallo-β-lactamase. J. Antimicrob. Chemother. 52: 699-702
242. Poirel L., Heritier C., Podglajen I., Sougakoff W., Gutmann L. and Nordmann P. (2003) Emergence in Klebsiella pneumoniae of a chromosome-encoded SHV β-lactamase that compromises the efficacy of imipenem. Antimicrob. Agents Chemother. 47: 755-758
243. Bonnet R., Marchandin H., Chanal C., Sirot D., Labia R., De Champs C. et al. (2002) Chromosome-encoded class D β-lactamase OXA-23 in Proteus mirabilis, Antimicrob. Agents Chemother. 46: 2004-2006
244. Lopez-Otsoa F., Gallego L., Towner K. J., Tysall L., Woodford N. and Livermore D. M. (2002) Endemic carbapenem resistance associated with OXA-40 carbapenemase among Acinetobacter baumannii isolates from a hospital in northern Spain. J. Clin. Microbiol. 40: 4741-4743.
245. Heritier C., Poirel L., Aubert D. and Nordmann P. (2003) Genetic and functional analysis of the chromosome-encoded carbapenem-hydrolyzing oxacillinase OXA-40 of Acinetobacter baumannii. Antimicrob. Agents Chemother. 47: 268-273
246. Poirel L., Heritier C., Tolun V. and Nordmann P. (2004) Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob. Agents Chemother. 48: 15-22
247. Poirel L., Heritier C. and Nordmann P. (2004) Chromosome-encoded Ambler class D β-lactamase of Shwanella oneidensis as a progenitor of carbapenem-hydrolyzing oxacillinase. Antimicrob. Agents Chemother. 48: 348-351
248. Hakenbeck R., Grebe T., Zahner D. and Stock J. B. (1999) β-lactam resistance in Streptococcus pneumoniae: penicillin-binding proteins and non-penicillin-binding proteins. Mol. Microbiol. 33: 673-678
249. Hsieh S. R. (2000) Antimicrobial susceptibility and species identification for clinical isolates of enterococci. J. Microbiol. Immunol. Infect. 33: 253-257
250. Dyke K. and Gregory P. (1997). Resistance to β-lactam antibiotics: resistance mediated by β-lactamases. In: The Staphyloccoci in Human Disease, pp. 139-157, Crossley K. B. and Archer G. L. (eds), Churchill Livingstone, New York
251. Smith M. C. and Murray B. E. (1992) Comparison of enterococcal and staphylococcal β-lactamase-encoding fragments. Antimicrob. Agents Chemother. 36: 273-276
252. Chambers H. F. (1997) Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. Clin. Microbiol. Rev. 10: 781-791
253. Chen Y., Succi J., Tenover F. C. and Koehler T. M. (2003) β-lactamase genes of the penicillin-susceptible Bacillus anthracis Sterne strain. J. Bacteriol. 185: 823-830
254. Materon I. C., Queenan A. M., Koehler T. M., Bush K. and Palzkill T. (2003) Biochemical characterization of β-lactamases Bla1 and Bla2 from Bacillus anthracis. Antimicrob. Agents Chemother. 47: 2040-2042
255. Cavallo J. D., Ramisse F., Girardet M., Vaissaire J., Mock M. and Hernandez E. (2002) Antibiotic susceptibilities of 96 isolates of Bacillus anthracis isolated in France between 1994 and 2000. Antimicrob. Agents Chemother. 46: 2307-2309
256. Segura C., Salvado M., Collado I., Chaves J. and Coira A. (1998) Contribution of β-lactamases to β-lactam susceptibilities of susceptible and multidrug-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob. Agents Chemother. 42: 1524-1526
257. Kwon H. H., Tomioka H. and Saito H. (1995) Distribution and characterization of β-lactamases of mycobacteria and related organisms. Tuber. Lung Dis. 76: 141-148
258. Voladri R. K., Lakey D. L., Hennigan S. H., Menzies B. E., Edwards K. M. and Kernodle D. S. (1998) Recombinant expression and characterization of the major β-lactamase of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 42: 1375-1381
259. Watanabe H., Hoshino K., Sugita R., Asoh N., Watanabe K., Oishi K. et al. (2004) Possible high rate of transmission of nontypeable Haemophilus influenzae, including β-lactamase-negative ampicillin-resistant strains, between children and their parents. J. Clin. Microbiol. 42: 362-365
260. Kobayashi I., Kanayama A., Saika T., Nishida M., Nakayama H., Tanaka M. et al. (2003) Tendency toward increase in the frequency of isolation of β-lactamase-nonproducing Neisseria gonorrhoeae exhibiting penicillin resistance, and recent emergence of multidrug-resistant isolates in Japan. J. Infect. Chemother. 9: 126-130
261. Richter S. S., Gordon K. A., Rhomberg P. R., Pfaller M. A. and Jones R. N. (2001) Neisseria meningitidis with decreased susceptibility to penicillin: report from the SENTRY antimicrobial surveillance program, North America, 1998-99. Diagn. Microbiol. Infect. Dis. 41: 83-88
262. Dabernat H., Delmas C., Seguy M., Pelissier R., Faucon G., Bennamani S. et al. (2002) Diversity of β-lactam resistance-conferring amino acid substitutions in penicillin-binding protein 3 of Haemophilus influenzae. Antimicrob. Agents Chemother. 46: 2208-2218
263. Straker K., Wootton M., Simm A. M., Bennett P. M., MacGowan A. P. and Walsh T. R. (2003) Cefuroxime resistance in non-β-lactamase Haemophilus influenzae is linked to mutations in ftsI. J. Antimicrob. Chemother. 51: 523-530
264. Matic V., Bozdogan B., Jacobs M. R., Ubukata K. and Appelbaum P. C. (2003) Contribution of β-lactamase and PBP amino acid substitutions to amoxicillin/clavulanate resistance in β-lactamase-positive, amoxicillin/clavulanate-resistant Haemophilus influenzae. J. Antimicrob. Chemother. 52: 1018-1021
265. Hasegawa K., Yamamoto K., Chiba N., Kobayashi R., Nagai K., Jacobs M. R. et al. (2003) Diversity of ampicillin-resistance genes in Haemophilus influenzae in Japan and the United States. Microb. Drug Resist. 9: 39-46
266. Ropp P. A., Hu M., Olesky M. and Nicholas R. A. (2002) Mutations in pona, the gene encoding penicillin-binding protein 1, and a novel locus, penC, are required for high-level chromosomally mediated penicillin resistance in Neisseria gonorrhoeae. Antimicrob. Agents Chemother. 46: 769-777
267. Ameyama S., Onodera S., Takahata M., Minami S., Maki N., Endo K. et al. (2002) Mosaic-like structure of penicillin-binding protein 2 Gene (penA) in clinical isolates of Neisseria gonorrhoeae with reduced susceptibility to cefixime. Antimicrob. Agents Chemother. 46: 3744-3749
268. Muratani T., Akasaka S., Kobayashi T., Yamada Y., Inatomi H., Takahashi K. et al. (2001) Outbreak of cefozopran (penicillin, oral cephems and aztreonam)-resistant Neisseria gonorrhoeae in Japan. Antimicrob. Agents Chemother. 45: 3603-3606
269. Antignac A., Kriz P., Tzanakaki G., Alonso J. M. and Taha M. K. (2001) Polymorphism of Neisseria meningitidis penA gene associated with reduced susceptibility to penicillin. J. Antimicrob. Chemother. 47: 285-296
270. Orus P. and Vinas M. (2001) Mechanisms other than penicillin-binding protein-2 alterations may contribute to moderate penicillin resistance in Neisseria meningitidis. Int. J. Antimicrob. Agents 18: 113-119
271. Antignac A., Boneca I. G., Rousselle J. C., Namane A., Carlier J. P., Vazquez J. A. et al. (2003) Correlation between alterations of the penicillin-binding protein 2 and modifications of the peptidoglycan structure in Neisseria meningitidis with reduced susceptibility to penicillin G. J. Biol. Chem. 278: 31529-31535
272. Fernandez-Cuenca F., Martinez-Martinez L., Conejo M. C., Ayala J. A., Perea E. J. et al. (2003) Relationship between β-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii. J. Antimicrob. Chemother. 51: 565-574
273. Neuwirth C., Siebor E., Duez J. M., Pechinot A. and Kazmierczak A. (1995) Imipenem resistance in clinical isolates of Proteus mirabilis associated with alterations in penicillin-binding proteins. J. Antimicrob. Chemother. 36: 335-342
274. Fang H., Edlund C., Hedberg M. and Nord C. E. (2002) New findings in β-lactam and metronidazole resistant Bacteroides fragilis group. Int. J. Antimicrob. Agents 19: 361-370
275. Fang H., Edlund C., Nord C. E. and Hedberg M. (2002) Selection of cefoxitin-resistant Bacteroides thetaiotaomicron mutants and mechanisms involved in β-lactam resistance. Clin. Infect. Dis. 35: S47-S53
276. Theron M. M., van Rensburg M. N. and Chalkley L. J. (2003) Penicillin-binding proteins involved in high-level piperacillin resistance in Veillonella spp. J. Antimicrob. Chemother. 52: 120-122
277. Ghosh A. S., Kar A. K. and Kundu M. (1998) Alterations in high molecular mass penicillin-binding protein 1 associated with β-lactam resistance in Shigella dysenteriae. Biochem. Biophys. Res. Commun. 248: 669-672
278. Gotoh N., Nunomura K. and Nishino T. (1990) Resistance of Pseudomonas aeruginosa to cefsulodin: modification of penicillin-binding protein 3 and mapping of its chromosomal gene. J. Antimicrob. Chemother. 25: 513-523
279. Gerrits M. M., Schuijffel D., van Zwet A. A., Kuipers E. J., Vandenbroucke-Grauls C. M. and Kusters J. G. (2002) Alterations in penicillin-binding protein 1A confer resistance to β-lactam antibiotics in Helicobacter pylori. Antimicrob. Agents Chemother. 46: 2229-2233
280. Kwon D. H., Dore M. P., Kim J. J., Kato M., Lee M., Wu J. Y. et al. (2003) High-level β-lactam resistance associated with acquired multidrug resistance in Helicobacter pylori. Antimicrob. Agents Chemother. 47: 2169-2178
281. Sapunaric F., Franssen C., Stefanic P., Amoroso A., Dardenne O. and Coyette J. (2003) Redefining the role of psr in β-lactam resistance and cell autolysis of Enterococcus hirae. J. Bacteriol. 185: 5925-5935
282. Duez C., Zorzi W., Sapunaric F., Amoroso A., Thamm I. and Coyette J. (2001) The penicillin resistance of Enterococcus faecalis JH2-2r results from an overproduction of the low-affinity penicillin-binding protein PBP4 and does not involve a psr-like gene. Microbiology 147: 2561-2569
283. Rybkine T., Mainardi J. L., Sougakoff W., Collatz E. and Gutmann L. (1998) Penicillin-binding protein 5 sequence alterations in clinical isolates of Enterococcus faecium with different levels of β-lactam resistance. J. Infect. Dis. 178: 159-163
284. Jureen R., Top J., Mohn S. C., Harthug S., Langeland N. and Willems R. J. (2003) Molecular characterization of ampicillin-resistant Enterococcus faecium isolates from hospitalized patients in Norway. J. Clin. Microbiol. 41: 2330-2336
285. El Amin N., Lund B., Tjernlund A., Lundberg C., Jalakas K. and Wretlind B. (2001) Mechanisms of resistance to imipenem in imipenem-resistant, ampicillin-sensitive Enterococcus faecium. APMIS 109: 791-796
286. Comenge Y., Quintiliani R. Jr, Li L., Dubost L., Brouard J.-P., Hugonnet J.-E. et al. (2003) The CroRS two-component regulatory system is required for intrinsic β-lactam resistance in Enterococcus faecalis. J. Bacteriol. 185: 7184-7192
287. Mainardi J. L., Morel V., Fourgeaud M., Cremniter J., Blanot D., Legrand R. et al. (2002) Balance between two transpeptidation mechanisms determines the expression of β-lactam resistance in Enterococcus faecium. J. Biol. Chem. 277: 35801-35807
288. Ohsaki Y., Tachibana M., Nakanishi K., Nakao S., Saito K., Toyoshima E. et al. (2003) Alterations in penicillin binding protein gene of Streptococcus pneumoniae and their correlation with susceptibility patterns. Int. J. Antimicrob. Agents 22: 140-146
289. Nichol K. A., Zhanel G. G. and Hoban D. J. (2002) Penicillin-binding protein 1A, 2B and 2X alterations in Canadian isolates of penicillin-resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 46: 3261-3264
290. du P. M., Bingen E. and Klugman K. P. (2002) Analysis of penicillin-binding protein genes of clinical isolates of Streptococcus pneumoniae with reduced susceptibility to amoxicillin. Antimicrob. Agents Chemother. 46: 2349-2357
291. Beall B., McEllistrem M. C., Gertz R. E. Jr, Boxrud D. J., Besser J. M., Harrison L. H. et al. (2002) Emergence of a novel penicillin-nonsusceptible, invasive serotype 35B clone of Streptococcus pneumoniae within the United States. J. Infect. Dis. 186: 118-122
292. Nagai K., Davies T. A., Jacobs M. R. and Appelbaum P. C. (2002) Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci. Antimicrob. Agents Chemother. 46: 1273-1280
293. Chambers H. F. (1999) Penicillin-binding protein-mediated resistance in pneumococci and staphylococci. J. Infect. Dis. 179 Suppl. 2: S353-S359
294. Hakenbeck R., Kaminski K., Konig A., van der L. M., Paik J., Reichmann P. et al. (1999) Penicillin-binding proteins in β-lactam-resistant Streptococcus pneumoniae. Microb. Drug Resist. 5: 91-99
295. Smith A. M. and Klugman K. P. (2003) Site-specific mutagenesis analysis of PBP 1A from a penicillin-cephalosporin-resistant pneumococcal isolate. Antimicrob. Agents Chemother. 47: 387-389
296. Pernot L., Chesnel L., Legouellec A., Croize J., Vernet T., Dideberg O. et al. (2004) A PBP2x from a clinical isolate of Streptococcus pneumoniae exhibits an alternative mechanism for reduction of susceptibility to β-lactam antibiotics. J. Biol. Chem. 278: 44448-44456
297. Chesnel L., Pernot L., Lemaire D., Champelovier D., Croize J., Dideberg O. et al. (2003) The structural modifications induced by the M339F substitution in PBP2x from Streptococcus pneumoniae further decreases the susceptibility to β-lactams of resistant strains. J. Biol. Chem. 278: 44448-44456
298. Gordon E., Mouz N., Duee E. and Dideberg O. (2000) The crystal structure of the penicillin-binding protein 2x from Streptococcus pneumoniae and its acyl-enzyme form: implication in drug resistance. J. Mol. Biol. 299: 477-485
299. Rohrer S. and Berger-Bachi B. (2003) FemABX peptidyl transferases: a link between branched-chain cell wall peptide formation and β-lactam resistance in gram-positive cocci. Antimicrob. Agents Chemother. 47: 837-846
300. Fiser A., Filipe S. R. and Tomasz A. (2003) Cell wall branches, penicillin resistance and the secrets of the MurM protein. Trends Microbiol. 11: 547-553
301. Giammarinaro P., Sicard M. and Gasc A. M. (1999) Genetic and physiological studies of the CiaH-CiaR two-component signal-transducing system involved in cefotaxime resistance and competence of Streptococcus pneumoniae. Microbiology 145: 1859-1869
302. Hiramatsu K., Katayama Y., Yuzawa H. and Ito T. (2002) Molecular genetics of methicillin-resistant Staphylococcus aureus. Int. J Med. Microbiol. 292: 67-74
303. Berger-Bachi B. and Rohrer S. (2002) Factors influencing methicillin resistance in staphylococci. Arch. Microbiol. 178: 165-171
304. Stefani S. and Varaldo P. E. (2003) Epidemiology of methicillin-resistant staphylococci in Europe. Clin. Microbiol. Infect. 9: 1179-1186
305. Wielders C. L., Fluit A. C., Brisse S., Verhoef J. and Schmitz F. J. (2002) mecA gene is widely disseminated in Staphylococcus aureus population. J. Clin. Microbiol. 40: 3970-3975
306. Hanssen A. M., Kjeldsen G. and Sollid J. U. (2004) Local variants of staphylococcal cassette chromosome mec in sporadic methicillin-resistant Staphylococcus aureus and methicillinresistant coagulase-negative staphylococci: evidence of horizontal gene transfer? Antimicrob. Agents Chemother. 48: 285-296
307. Katayama Y., Zhang H. Z., Hong D. and Chambers H. F. (2003) Jumping the barrier to β-lactam resistance in Staphylococcus aureus. J. Bacteriol. 185: 5465-5472
308. Robinson D. A. and Enright M. C. (2003) Evolutionary models of the emergence of methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 47: 3926-3934
309. Pinho M. G., De Lencastre H. and Tomasz A. (2001) An acquired and a native penicillin-binding protein cooperate in building the cell wall of drug-resistant staphylococci. Proc. Natl. Acad. Sci. USA 98: 10886-10891
310. Gardete S., Ludovice A. M., Sobral R. G., Filipe S. R., De Lencastre H. and Tomasz A. (2004) Role of murE in the expression of β-lactam antibiotic resistance in Staphylococcus aureus. J. Bacteriol. 186: 1705-1713
311. Sobral R. G., Ludovice A. M., Gardete S., Tabei K., De Lencastre H. and Tomasz A. (2003) Normally functioning murF is essential for the optimal expression of methicillin resistance in Staphylococcus aureus. Microb. Drug Resist. 9: 231-241
312. De Jonge B. L., Gage D. and Xu N. (2002) The carboxyl terminus of peptidoglycan stem peptides is a determinant for methicillin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 46: 3151-3155
313. Kuroda M., Kuroda H., Oshima T., Takeuchi F., Mori H. and Hiramatsu K. (2003) Two-component system VraSR positively modulates the regulation of cell-wall biosynthesis pathway in Staphylococcus aureus. Mol. Microbiol. 49: 807-821
314. Galdiero E., Liguori G., D'Isanto M., Damiano N. and Sommese L. (2003) Distribution of mecA among methicillin-resistant clinical staphylococcal strains isolated at hospitals in Naples, Italy. Eur. J. Epidemiol. 18: 139-145
315. Yoshida R., Kuwahara-Arai K., Baba T., Cui L., Richardson J. F. and Hiramatsu K. (2003) Physiological and molecular analysis of a mecA-negative Staphylococcus aureus clinical strain that expresses heterogeneous methicillin resistance. J. Antimicrob. Chemother. 51: 247-255
316. Nikaido H. (2000) Crossing the envelope: how cephalosporins reach their targets. Clin. Microbiol. Infect. 6 Suppl. 3: 22-26
317. Clarke B., Hiltz M., Musgrave H. and Forward K. R. (2003) Cephamycin resistance in clinical isolates and laboratory-derived strains of Escherichia coli, Nova Scotia, Canada. Emerg. Infect. Dis. 9: 1254-1259
318. Oliver A., Weigel L. M., Rasheed J. K., McGowan J. E. Jr, Raney P. and Tenover F. C. (2002) Mechanisms of decreased susceptibility to cefpodoxime in Escherichia coli. Antimicrob. Agents Chemother. 46: 3829-3836
319. Weindorf H., Schmidt H. and Martin H. H. (1998) Contribution of overproduced chromosomal β-lactamase and defective outer membrane porins to resistance to extended-spectrum β-lactam antibiotics in Serratia marcescens. J. Antimicrob. Chemother. 41: 189-195
320. Poole K. (2002) Outer membranes and efflux: the path to multidrug resistance in gram-negative bacteria. Curr. Pharm. Biotechnol. 3: 77-98
321. Domenech-Sanchez A., Martinez-Martinez L., Hernandez-Alles S., del Carmen C. M., Pascual A., Tomas J. M. et al. (2003) Role of Klebsiella pneumoniae OmpK35 porin in antimicrobial resistance. Antimicrob. Agents Chemother. 47: 3332-3335
322. TEM-1 variants: their role in β-lactam resistance in Klebsiella pneumoniae, J. Antimicrob. Chemother. 52: 899-903
323. Gayet S., Chollet R., Molle G., Pages J. M. and Chevalier J. (2003) Modification of outer membrane protein profile and evidence suggesting an active drug pump in Enterobacter aerogenes clinical strains. Antimicrob. Agents Chemother. 47: 1555-1559
324. Yigit H., Anderson G. J., Biddle J. W., Steward C. D., Rasheed J. K., Valera L. L. et al. (2002) Carbapenem resistance in a clinical isolate of Enterobacter aerogenes is associated with decreased expression of OmpF and OmpC porin analogs. Antimicrob. Agents Chemother. 46: 3817-3822
325. Sturenburg E., Sobottka I., Mack D. and Laufs R. (2002) Cloning and sequencing of Enterobacter aerogenes OmpC-type osmoporin linked to carbapenem resistance. Int. J. Med. Microbiol. 291: 649-654
326. Mukhopadhyay S. and Chakrabarti P. (1997) Altered permeability and β-lactam resistance in a mutant of Mycobacterium smegmatis. Antimicrob. Agents Chemother. 41: 1721-1724
327. Pirnay J. P., de Vos D., Mossialos D., Vanderkelen A., Cornelis P. and Zizi M. (2002) Analysis of the Pseudomonas aeruginosa oprD gene from clinical and environmental isolates. Environ. Microbiol. 4: 872-882
328. Horii T., Muramatsu H., Morita M. and Maekawa M. (2003) Characterization of Pseudomonas aeruginosa isolates from patients with urinary tract infections during antibiotic therapy. Microb. Drug Resist. 9: 223-229
329. Pai H., Kim J., Kim J., Lee J. H., Choe K. W. and Gotoh N. (2001) Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 45: 480-484
330. Limansky A. S., Mussi M. A. and Viale A. M. (2002) Loss of a 29-kilodalton outer membrane protein in Acinetobacter baumannii is associated with imipenem resistance. J. Clin. Microbiol. 40: 4776-4778
331. Conejo M. C., Martinez-Martinez L., Garcia I., Picabea L. and Pascual A. (2003) Effect of siliconized latex urinary catheters on the activity of carbapenems against Pseudomonas aeruginosa strains with defined mutations in ampC, oprD and genes coding for efflux systems. Int. J. Antimicrob. Agents 22: 122-127
332. Conejo M. C., Garcia I., Martinez-Martinez L., Picabea L. and Pascual A. (2003) Zinc eluted from siliconized latex urinary catheters decreases OprD expression, causing carbapenem resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 47: 2313-2315
333. Perron K., Caille O., Rossier C., Van Delden C., Dumas J. L. and Kohler T. (2004) CZCR-CZCS: a two component system involved in heavy metal and carbapenem resistance in Pseudomonas aeruginosa. J. Biol. Chem. 279: 8761-8768
334. Poole K. (2004) Efflux-mediated multiresistance in Gram-negative bacteria. Clin. Microbiol. Infect. 10: 12-26
335. Li X. Z. and Nikaido H. (2004) Efflux-mediated drug resistance in bacteria. Drugs 64: 159-204
336. Masuda N., Sakagawa E., Ohya S., Gotoh N., Tsujimoto H. and Nishino T. (2000) Substrate specificities of MexAB-OprM, MexCD-OprJ and MexXY-OprM efflux pumps in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44: 3322-3327
337. Okamoto K., Gotoh N. and Nishino T. (2002) Alterations of susceptibility of Pseudomonas aeruginosa by overproduction of multidrug efflux systems, MexAB-OprM, MexCD-OprJ and MexXY/OprM to carbapenems: substrate specificities of the efflux systems. J Infect. Chemother 8: 371-373
338. Bornet C., Chollet R., Mallea M., Chevalier J., Davin-Regli A., Pages J. M. et al. (2003) Imipenem and expression of multidrug efflux pump in Enterobacter aerogenes. Biochem. Biophys. Res. Commun. 301: 985-990
339. Kallman O., Fendukly F., Karlsson I. and Kronvall G. (2003) Contribution of efflux to cefuroxime resistance in clinical isolates of Escherichia coli. Scand. J. Infect. Dis. 35: 464-470
340. Okamoto K., Gotoh N. and Nishino T. (2001) Pseudomonas aeruginosa reveals high intrinsic resistance to penem antibiotics: penem resistance mechanisms and their interplay. Antimicrob. Agents Chemother. 45: 1964-1971
341. Okamoto K., Gotoh N. and Nishino T. (2002) Extrusion of penem antibiotics by multicomponent efflux systems MexAB-OprM, MexCD-OprJ and MexXY-OprM of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 46: 2696-2699
342. Poole K. (2003) Overcoming multidrug resistance in Gram-negative bacteria. Curr. Opin. Investig. Drugs 4: 139
343. Abbanat D., Macielag M. and Bush K. (2003) Novel antibacterial agents for the treatment of serious Gram-positive infections. Expert. Opin. Investig. Drugs 12: 379-399
344. Khare M. and Keady D. (2003) Antimicrobial therapy of methicillin resistant Staphylococcus aureus infection. Expert. Opin. Pharmacother. 4: 165-177
345. Bush K. (2002) The impact of β-lactamases on the development of novel antimicrobial agents. Curr. Opin. Investig. Drugs 3: 1284-1290
346. Lee N., Yuen K. Y. and Kumana C. R. (2003) Clinical role of β-lactam/β-lactamase inhibitor combinations. Drugs 63: 1511-1524
347. Sandanayaka V. P. and Prashad A. S. (2002) Resistance to β-lactam antibiotics: structure and mechanism based design of β-lactamase inhibitors. Curr. Med. Chem. 9: 1145-1165
348. Alba J., Ishii Y., Galleni M., Frere J. M., Ito M. and Yamaguchi K. (2002) Cefcapene inactivates chromosome-encoded class C β-lactamases. J. Infect. Chemother. 8: 207-210
349. Jamieson C. E., Lambert P. A. and Simpson I. N. (2003) In vitro and in vivo activities of AM-112, a novel oxapenem. Antimicrob. Agents Chemother. 47: 1652-1657
350. Jamieson C. E., Lambert P. A. and Simpson I. N. (2003) In vitro activities of novel oxapenems, alone and in combination with ceftazidime, against gram-positive and gram-negative organisms. Antimicrob. Agents Chemother. 47: 2615-2618
351. Simpson I. N., Urch C. J., Hagen G., Albrecht R., Sprinkart B. and Pfaendler H. R. (2003) Synthesis and biological activity of AM-112 and related oxapenem analogues. J. Antibiot. (Tokyo) 56: 838-847
352. Page M. I., Hinchliffe P. S., Wood J. M., Harding L. P. and Laws A. P. (2003) Novel mechanism of inhibiting β-lactamases by sulfonylation using β-sultams. Bioorg. Med. Chem. Lett. 13: 4489-4492
353. Vilar M., Galleni M., Solmajer T., Turk B., Frere J. M. and Matagne A. (2001) Kinetic study of two novel enantiomeric tricyclic beta-lactams which efficiently inactivate class C β-lactamases. Antimicrob. Agents Chemother. 45: 2215-2223
354. Morandi F., Caselli E., Morandi S., Focia P. J., Blazquez J., Shoichet B. K. et al. (2003) Nanomolar inhibitors of AmpC β-lactamase. J. Am. Chem. Soc. 125: 685-695
355. Kaur K., Adediran S. A., Lan M. J. and Pratt R. F. (2003) Inhibition of β-lactamases by monocyclic acyl phosph(on)ates. Biochemistry 42: 1529-1536
356. Cao X., Iqbal A., Patel A., Gretz P., Huang G., Crowder M. et al. (2003) 3-alkoxy-5-isoxazolidinones mimic β-lactams. Biochem. Biophys. Res. Commun. 311: 267-271
357. Siemann S., Evanoff D. P., Marrone L., Clarke A. J., Viswanatha T. and Dmitrienko G. I. (2002) N-arylsulfonyl hydrazones as inhibitors of IMP-1 metallo-β-lactamase. Antimicrob. Agents Chemother. 46: 2450-2457
358. Payne D. J., Hueso-Rodriguez J. A., Boyd H., Concha N. O., Janson C. A., Gilpin M. et al. (2002) Identification of a series of tricyclic natural products as potent broad-spectrum inhibitors of metallo-β-lactamases. Antimicrob. Agents Chemother. 46: 1880-1886
359. Boerzel H., Koeckert M., Bu W., Spingler B. and Lippard S. J. (2003) Zinc-bound thiolate-disulfide exchange: a strategy for inhibiting metallo-β-lactamases. Inorg. Chem. 42: 1604-1615
360. Siemann S., Clarke A. J., Viswanatha T. and Dmitrienko G. I. (2003) Thiols as classical and slow-binding inhibitors of IMP-1 and other binuclear metallo-β-lactamases. Biochemistry 42: 1673-1683
361. Garcia-Saez I., Hopkins J., Papamicael C., Franceschini N., Amicosante G., Rossolini G. M. et al. (2003) The 1.5-A structure of Chryseobacterium meningosepticum zinc β-lactamase in complex with the inhibitor, D-captopril. J. Biol. Chem. 278: 23868-23873
362. Beharry Z., Chen H., Gadhachanda V. R., Buynak J. D. and Palzkill T. (2004) Evaluation of penicillin-based inhibitors of the class A and B β-lactamases from Bacillus anthracis. Biochem. Biophys. Res. Commun. 313: 541-545
363. Buynak J. D., Chen H., Vogeti L., Gadhachanda V. R., Buchanan C. A., Palzkill T. et al. (2004) Penicillin-derived inhibitors that simultaneously target both metallo- and serine-β-lactamases. Bioorg. Med. Chem. Lett. 14: 1299-1304
364. Sandanayaka V. P., Prashad A. S., Yang Y., Williamson R. T., Lin Y. I. and Mansour T. S. (2003) Spirocyclopropyl β-lactams as mechanism-based inhibitors of serine β-lactamases. Synthesis by rhodium-catalyzed cyclopropanation of 6-diazopenicillanate sulfone. J. Med. Chem. 46: 2569-2571
365. Nukaga M., Abe T., Venkatesan A. M., Mansour T. S., Bonomo R. A. and Knox J. R. (2003) Inhibition of class A and class C β-lactamases by penems: crystallographic structures of a novel 1,4-thiazepine intermediate. Biochemistry 42: 13152-13159
366. Padayatti P. S., Helfand M. S., Totir M. A., Carey M. P., Hujer A. M., Carey P. R. et al. (2004) Tazobactam forms a stoichiometric trans-enamine intermediate in the E166A variant of SHV-1 β-lactamase: 1.63 Å crystal structure. Biochemistry 43: 843-848
367. Smyth T. P., O'Donnell M. E., O'Connor M. J. and St Ledger J. O. (2000) β-lactamase-dependent prodrugs - recent developments. Tetrahedron 56: 5699-5707
368. Stone G. W., Zhang Q., Castillo R., Doppalapudi V. R., Bueno A. R., Lee J. Y. et al. (2004) Mechanism of action of NB2001 and NB2030, novel antibacterial agents activated by β-lactamases. Antimicrob. Agents Chemother. 48: 477-483
369. Long T. E. (2003) Recent progress toward the clinical development of new anti-MRSA antibiotics. IDrugs. 6: 351-359
370. Deshpande L. M. and Jones R. N. (2003) Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci. Clin. Microbiol. Infect. 9: 1120-1124
371. Malouin F., Blais J., Chamberland S., Hoang M., Park C., Chan C. et al. (2003) RWJ-54428 (MC-02,479), a new cephalosporin with high affinity for penicillin-binding proteins, including PBP 2a, and stability to staphylococcal β-lactamases. Antimicrob. Agents Chemother. 47: 658-664
372. Griffith D. C., Harford L., Williams R., Lee V. J. and Dudley M. N. (2003) In vivo antibacterial activity of RWJ-54428, a new cephalosporin with activity against gram-positive bacteria. Antimicrob. Agents Chemother. 47: 43-47
373. Tsuji M., Takema M., Miwa H., Shimada J. and Kuwahara S. (2003) In vivo antibacterial activity of S-3578, a new broad-spectrum cephalosporin: methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa experimental infection models. Antimicrob. Agents Chemother. 47: 2507-2512
374. Fujimura T., Yamano Y., Yoshida I., Shimada J. and Kuwahara S. (2003) In vitro activity of S-3578, a new broad-spectrum cephalosporin active against methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 47: 923-931
375. Clark J., Fung-Tomc J. C., Minassian B., Tsai Y. H., Yang H., Huczko E. et al. (2002) In vitro and in vivo activities of a novel cephalosporin, BMS-247243, against organisms other than staphylococci. Antimicrob. Agents Chemother. 46: 1108-1111
376. Ida T., Tsushima M., Ishii T., Atsumi K. and Tamura A. (2002) CP6679, a new injectable cephalosporin with broad spectrum and potent activities against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. J. Infect. Chemother. 8: 138-144
377. Sader H. S., Johnson D. M. and Jones R. N. (2004) In vitro activities of the novel cephalosporin LB 11058 against multidrug-resistant Staphylococci and Streptococci. Antimicrob. Agents Chemother. 48: 53-62
378. Springer D. M., Luh B. Y., Goodrich J. T. and Bronson J. J. (2003) Anti-MRSA cephems. Part 3: additional C-7 acid derivatives. Bioorg. Med. Chem 11: 281-291
379. Springer D. M., Luh B. Y., Goodrich J. and Bronson J. J. (2003) Anti-MRSA cephems. Part 2: C-7 cinnamic acid derivatives. Bioorg. Med. Chem. 11: 265-279
380. Jones R. N., Deshpande L. M., Mutnick A. H. and Biedenbach D. J. (2002) In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J. Antimicrob. Chemother. 50: 915-932
381. Aihara K., Kano Y., Shiokawa S., Sasaki T., Setsu F., Sambongi Y. et al. (2003) CP0569, a new broad-spectrum injectable carbapenem. Part 1: synthesis and structure-activity relationships. Bioorg. Med. Chem. 11: 3475-3485
382. Ueda Y. and Sunagawa M. (2003) In vitro and in vivo activities of novel 2-(thiazol-2-ylthio)-1β-methylcarbapenems with potent activities against multiresistant gram-positive bacteria. Antimicrob. Agents Chemother. 47: 2471-2480
383. Katayama Y., Zhang H. Z. and Chambers H. F. (2004) PBP 2a mutations producing very-high-level resistance to β-lactams. Antimicrob. Agents Chemother. 48: 453-459
384. Sauvage E., Kerff F., Fonze E., Herman R., Schoot B., Marquette J. P. et al. (2002) The 2.4-A crystal structure of the penicillin-resistant penicillin-binding protein PBP5fm from Enterococcus faecium in complex with benzylpenicillin. Cell. Mol. Life Sci. 59: 1223-1232
385. Lim D. and Strynadka N. C. (2002) Structural basis for the β-lactam resistance of PBP2a from methicillin-resistant Staphylococcus aureus. Nat. Struct. Biol. 9: 870-876
386. Lee M., Hesek D., Suvorov M., Lee W., Vakulenko S. and Mobashery S. (2003) A mechanism-based inhibitor targeting the DD-transpeptidase activity of bacterial penicillin-binding proteins. J. Am. Chem. Soc. 125: 16322-16326
387. Pechenov A., Stefanova M. E., Nicholas R. A., Peddi S. and Gutheil W. G. (2003) Potential transition state analogue inhibitors for the penicillin-binding proteins. Biochemistry 42: 579-588
388. Chandrakala B., Shandil R. K., Mehra U., Ravishankar S., Kaur P., Usha V. et al. (2004) High-throughput screen for inhibitors of transglycosylase and/or transpeptidase activities of Escherichia coli penicillin binding protein lb. Antimicrob. Agents Chemother. 48: 30-40
389. Zervosen A., Lu W. P., Chen Z., White R. E., Demuth T. P. Jr and Frere J. M. (2004) Interactions between penicillin-binding proteins (PBPs) and two novel classes of PBP inhibitors, arylalkylidene rhodanines and arylalkylidene iminothiazolidin-4-ones. Antimicrob. Agents Chemother. 48: 961-969
390. Shibata H., Shirakata C., Kawasaki H., Sato Y., Kuwahara T., Ohnishi Y. et al. (2003) Flavone markedly affects phenotypic expression of β-lactam resistance in methicillin-resistant Staphylococcus aureus strains isolated clinically. Biol. Pharm. Bull. 26: 1478-1483
391. Sato Y., Shibata H., Arakaki N. and Higuti T. (2004) 6,7-dihydroxyflavone dramatically intensifies the susceptibility of methicillin-resistant or -sensitive Staphylococcus aureus to β-lactams. Antimicrob. Agents Chemother. 48: 1357-1360
392. Hu Z. Q., Zhao W. H., Asano N., Yoda Y., Hara Y. and Shimamura T. (2002) Epigallocatechin gallate synergistically enhances the activity of carbapenems against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 46: 558-560
393. Zhao W. H., Hu Z. Q., Okubo S., Hara Y. and Shimamura T. (2001) Mechanism of synergy between epigallocatechin gallate and β-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 45: 1737-1742
394. Yamada H., Ohashi K., Atsumi T., Okabe H., Shimizu T., Nishio S. et al. (2003) Effects of tea catechin inhalation on methicillin-resistant Staphylococcus aureus in elderly patients in a hospital ward. J. Hosp. Infect. 53: 229-231
395. Shimizu M., Shiota S., Mizushima T., Ito H., Hatano T., Yoshida T. et al. (2001) Marked potentiation of activity of β-lactams against methicillin-resistant Staphylococcus aureus by corilagin. Antimicrob. Agents Chemother. 45: 3198-3201
396. Kristiansen M. M., Leandro C., Ordway D., Martins M., Viveiros M., Pacheco T. et al. (2003) Phenothiazines alter resistance of methicillin- resistant strains of Staphylococcus aureus (MRSA) to oxacillin in vitro. Int. J. Antimicrob. Agents 22: 250-253
397. Du B., Long Y., Liu H., Chen D., Liu D., Xu Y. et al. (2002) Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome. Intensive Care Med. 28: 1718-1723
398. Lan C. K., Hsueh P. R., Wong W. W., Fung C. P., Lau Y. T., Yeung J. Y. et al. (2003) Association of antibiotic utilization measures and reduced incidence of infections with extended-spectrum β-lactamase-producing organisms. J. Microbiol. Immunol. Infect. 36: 182-186
399. Du B., Chen D., Liu D., Long Y., Shi Y., Wang H. et al. (2003) Restriction of third-generation cephalosporin use decreases infection-related mortality. Crit. Care Med. 31: 1088-1093
400. Lee K., Lim Y. S., Yong D., Yum J. H. and Chong Y. (2003) Evaluation of the Hodge test and the imipenem-EDTA double-disk synergy test for differentiating metallo-β-lactamase-producing isolates of Pseudomonas spp. and Acinetobacter spp. J. Clin. Microbiol. 41: 4623-4629
401. Engemann J. J., Carmeli Y., Cosgrove S. E., Fowler V. G., Bronstein M. Z., Trivette S. L. et al. (2003) Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin. Infect. Dis. 36: 592-598
402. Chediac-Tannoury R. and Araj G. F. (2003) Rapid MRSA detection by a latex kit. Clin. Lab Sci. 16: 198-202
403. Fang H. and Hedin G. (2003) Rapid screening and identification of methicillin-resistant Staphylococcus aureus from clinical samples by selective-broth and real-time PCR assay. J. Clin. Microbiol. 41: 2894-2899
404. Elsayed S., Chow B. L., Hamilton N. L., Gregson D. B., Pitout J. D. and Church D. L. (2003) Development and validation of a molecular beacon probe-based real-time polymerase chain reaction assay for rapid detection of methicillin resistance in Staphylococcus aureus. Arch. Pathol. Lab Med. 127: 845-849